EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Curriculum Vitae

Personal information

Inne Crèvecoeur

Work experience

1. Employer: Sciensano
   - Start date: 01-2021
   - End date:
   - Position: Clinical Evaluator
   - Activities: Clinical Evaluator for Vaccines at FAGG
   - Country: Belgium
2. Employer: Merck Sharp & Dohme
   - Start date: 10-2017
   - End date: 12-2020
   - Position: Early Stage Development Scientist
   - Activities: Managing Phase I clinical trials
   - Country: Belgium

Education and training

1. Subject: PhD KU Leuven
   - Start date: 2012
   - End date: 2017
   - Qualification: PhD in Biomedical Sciences: 'Interaction between the beta_cell and the immune system in Type 1 Diabetes: role for post_translational modifications' _ Promotor: Prof. Dr. Chantal Mathieu
   - Organisation: KU Leuven
   - Country: Belgium
2. Subject: Master KU Leuven
   - Start date: 2010
   - End date: 2012
   - Qualification: Master in Biomedical Sciences
   - Organisation: KU Leuven
   - Country: Belgium
3. Subject: Bachelor KU Leuven
   - Start date: 2007
   - End date: 2010
   - Qualification: Bachelor in Biomedical Sciences
   - Organisation: KU Leuven
   - Country: Belgium

Additional information

Publications

Johns DG, Campeau LC, Banka P, Bautmans A, Bueters T, Bianchi E, Branca D, Bulger PG, Crevecoeur I, Ding FX, Garbaccio RM, Guetschow ED, Guo Y, Ha SN, Johnston JM, Josien H, Kauh EA, Koeplinger KA, Kuethe JT, Lai E, Lanning CL, Lee AYH, Li L, Nair AG, O'Neill EA, Stoch SA, Thaisrivongs DA, Tucker TJ, Vachal P, van Dyck K, Vanhoutte FP, Volckaert B, Wolford DG, Xu A, Zhao T, Zhou D, Zhou S, Zhu X, Zokian HJ, Walji A, Wood HB. Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor. Circulation. 2023 May 1. doi: 10.1161/CIRCULATIONAHA.122.063372.

Vig S, Buitinga M, Rondas D, Crèvecoeur I, van Zandvoort M, Waelkens E, Eizirik DL, Gysemans C, Baatsen P, Mathieu C, Overbergh L. Cytokine - induced translocation of GRP78 to the plasma membrane triggers a pro - apoptotic feedback loop in pancreatic beta cells. Cell Death Dis. 2019 Apr;10(4):309

Buitinga M, Callebaut A, Marques Câmara Sodré F, Crèvecoeur I, Blahnik - Fagan G, Yang ML, Bugliani M, Arribas - Layton D, Marré M, Cook DP, Waelkens E, Mallone R, Piganelli JD, Marchetti P, Mamula MJ, Derua R, James EA, Mathieu C, Overbergh L. Inflammation - Induced Citrullinated Glucose - Regulated Protein 78 Elicits Immune Responses in Human Type 1 Diabetes. Diabetes 2018 Nov;67(11):2337 - 2348

Crèvecoeur I, Vig S, Mathieu C, Overbergh L. Understanding type 1 diabetes through proteomics. Expert Rev Proteomics. 2017Jul;14(7):571 - 580.

Crèvecoeur I, Gudmundsdottir V, Vig S, Marques Camara Sodre F, D'Hertog W, Fierro AC, Van Lommel L, Gysemans C, Marchal K, Waelkens E, Schuit F, Brunak S, Overbergh L, Mathieu C. Combined microarray and proteomic analysis reveals early differences in islets from pre - diabetic NOD mice. Diabetologia. 2017 Mar;60(3):475 - 489.

Babon JA, DeNicola ME, Blodgett DM, Crèvecoeur I, Buttrick TS, Maehr R, Bottino R, Naji A, et al. Analysis of self - antigen specificity of islet - infiltrating T cells from human donors with type 1 diabetes. Nature Medicine. 2016 Dec;22(12):1482 - 1487. Rondas D, Gudmundsdottir V, D'Hertog W, Crèvecoeur I, Waelkens E, Brunak S, Mathieu C, Overbergh L. A proteomic study of the regulatory role for STAT - 1 in cytokine - induced beta - cell death. Proteomics Clin Appl. 2015 Oct;9(9 - 10):938 - 52.

Crèvecoeur I, Rondas D, Mathieu C, Overbergh L. The

beta - cell in type 1 diabetes: What have we learned from proteomic studies? Proteomics Clin Appl. 2015 Aug;9(7 - 8):755 - 66.

Rondas D*, Crèvecoeur I*, D'Hertog W, Ferreira GB, Staes A, Garg AD, Eizirik DL, Agostinis P, Gevaert K, Overbergh L, Mathieu C. Citrullinated glucose - regulated protein 78 is an autoantigen in type 1 diabetes. Diabetes. 2015 Feb;64(2):573 - 86. * shared first author

Projects

Memberships

Other Relevant Information